Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and cardiovascular death in women, compared to men2 Among patients who […]
Tag: Novartis
Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. As part of this launch, Novartis has licensed to Anthos MAA868, an […]
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
Basel, February 25, 2019 – Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy. […]
